辰欣药业(603367.SH)及控股子公司拟使用闲置自有资金进行委托理财及证券投资

Core Viewpoint - Chenxin Pharmaceutical (603367.SH) plans to utilize idle self-owned funds for entrusted wealth management and securities investment, with a total amount not exceeding RMB 2.9 billion [1] Group 1: Financial Allocation - The total amount for entrusted wealth management is capped at RMB 2.3 billion [1] - The total amount for securities investment is capped at RMB 600 million [1] - The usage period for the allocated funds is 12 months from the date of board approval [1]